Duane syndrome

Santgar Announces the Launch of Its Newest Medicine, "Excentera LS," Which Will Treat Immune-Mediated Disorders That Cause Dry Eyes in Dogs

Retrieved on: 
Tuesday, February 7, 2023
KCS, Cornea, Inflammation, Veterinarian, Conjunctiva, DVM, Dog, Duane syndrome, PTF, PETS, Eye, Animal, Disease, Research, Veterinary medicine, Pharmaceutical industry

Excentera LS is an innovative therapeutic option for veterinarians and pet owners to treat eye diseases.

Key Points: 
  • Excentera LS is an innovative therapeutic option for veterinarians and pet owners to treat eye diseases.
  • It is a once-per-month, easy-to-administer solution that can help restore eye comfort and vision to dogs and other pets suffering from dry eye.
  • Santgar also has an entire education division dedicated to teaching veterinarians how to use and administer their products most effectively.
  • Santgar's major differentiator in providing innovative medical solutions is its ability to produce and share knowledge to grow with its clients.

Santgar Has Officially Announced its Newest Product, "Excentera LS," Which Will Treat Immune-Mediated Diseases in Dogs That Cause Dry Eye

Retrieved on: 
Saturday, February 4, 2023
Disease, Health, Veterinarian, Dog, Duane syndrome, KCS, Quality of life, Animal, Conjunctiva, PETS, PTF, Cornea, Knowledge, Research, Eye, Inflammation, Pharmaceutical industry, Veterinary medicine

"We are proud to be launching Excentera LS, an innovative medication that promises to help improve the quality of life of dogs suffering from dry eye," says Diego García Santisteban, CEO of Santgar.

Key Points: 
  • "We are proud to be launching Excentera LS, an innovative medication that promises to help improve the quality of life of dogs suffering from dry eye," says Diego García Santisteban, CEO of Santgar.
  • KCS is a common disease that causes dry eye in dogs.
  • Excentera LS is an innovative therapeutic option for veterinarians and pet owners to treat eye diseases.
  • It is a once-per-month, easy-to-administer solution that can help restore eye comfort and vision to dogs and other pets suffering from dry eye.

Sight Sciences Announces 1,000th TearCare® Customer Installation

Retrieved on: 
Thursday, January 26, 2023
Cornea, Exocrine gland, Insurance, MD, MGD, Duane syndrome, Trial of the century, AMA, Patient, RCT, FDA, Publishing, American Medical Association, Indian Medical Association, Pharmaceutical industry

MENLO PARK, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”) an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, announced today the 1,000th installation of its TearCare® System.

Key Points: 
  • MENLO PARK, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”) an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, announced today the 1,000th installation of its TearCare® System.
  • In 2019 Sight Sciences commercialized the TearCare® System with the knowledge that doctors, and patients were seeking improvements beyond those provided by current over the counter, prescription pharmaceutical, or in-office treatments for dry eye.
  • Desired improvements included faster action, enduring results and, in the case of in-office treatment, a price point allowing more practices to equip their offices.
  • Immediately following launch, Sight Sciences took the first step required to obtain access to coverage and payment for dry eye sufferers when the American Medical Association (AMA) granted a temporary procedural code specifically describing the open eye TearCare® procedure.

Global Dry Eye Syndrome Treatment Market Report 2022 to 2028: Featuring AbbVie, Novartis, Sun Pharmaceuticals Industries and OASIS Medical Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023
Pharmaceutical, Health, Optical, Plasma protein binding, Approved drug, DE, Therapy, Tears, Duane syndrome, Cornea, FDA, Eyelid, Irritation, Conjunctiva, Growth, Patient, Bausch & Lomb, Loteprednol, Dry eye syndrome, Clinical trial, DED, Eye, Market share, Investment, Mucus, Printed circuit board, Cosmetics, Hospital, Pharmaceutical industry, Dose

The Global Dry Eye Syndrome Treatment Market size is expected to reach $6.5 billion by 2028, rising at a market growth of 4.5% CAGR during the forecast period.

Key Points: 
  • The Global Dry Eye Syndrome Treatment Market size is expected to reach $6.5 billion by 2028, rising at a market growth of 4.5% CAGR during the forecast period.
  • As these development continue to proceed, they aid in the expansion of the dry eye syndrome treatment market.
  • This demonstrates significant drug approval costs that are expected to have an impact on the market for dry eye medications.
  • Additionally, long waiting times also add up to lost money for these manufacturers, and as such hampers the growth of the dry eye syndrome treatment market.

Dry Eye Products Global Market Report 2022: Featuring Novartis, Johnson and Johnson, AbbVie, Santen Pharmaceutical & More - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023
Pharmaceutical, Health, Optical, Royal Society of Medicine, Vision, World Health Organization, Therapy, OTC, COVID-19, Tears, Allergan, Sleep, National Health Service, CSR, Growth, Patient, Diet, Duane syndrome, Research, Clinical trial, Others, Association for Research in Vision and Ophthalmology, Eye, Incidence, Private sector, Exercise, Ciclosporin, Pharmaceutical industry, Cosmetics, Ophthalmology

Factors such as rising incidences of dry eye and the growing geriatric population drive the growth of dry eye products market.

Key Points: 
  • Factors such as rising incidences of dry eye and the growing geriatric population drive the growth of dry eye products market.
  • However, the side effects caused due to eye drops hamper the dry eye products market growth.
  • Therefore, the rising incidences of dry eyes are expected to propel the demand for dry eye products in the coming years.
  • Based on the product, the dry eye products market is segmented into artificial tears, antibiotic drops, hormone drops, and others.

Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs

Retrieved on: 
Tuesday, January 10, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Ilut, New Drug Application, Duane syndrome, Standard of care, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Keratoconus, Corporation, Safety, Dermis, FDA, Pilocarpine, Glaucoma, Eyelid, NYSE, NDA, Food, Patient, GKOS, DED, Eye, Retina, BID, Pharmaceutical industry, 1870 Glaukos

“These clinical updates represent meaningful milestones for two of our key Corneal Health pipeline programs and we look forward to continuing to advance both of these important programs forward in 2023,” said Thomas Burns, Glaukos chairman and chief executive officer.

Key Points: 
  • “These clinical updates represent meaningful milestones for two of our key Corneal Health pipeline programs and we look forward to continuing to advance both of these important programs forward in 2023,” said Thomas Burns, Glaukos chairman and chief executive officer.
  • Glaukos plans to randomize approximately 290 subjects in this trial and is targeting enrollment completion by the end of 2023.
  • Glaukos also announced promising topline results from its Phase 2a first-in-human clinical trial for GLK-301 (iLution – Dry Eye Disease (DED)) for the signs and symptoms of DED.
  • Based on these encouraging observations, Glaukos plans to advance GLK-301 into a Phase 2b clinical trial targeted to begin in 2023.

Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Monday, January 9, 2023
Surgical instrument, Glaucoma, Duane syndrome, CFO, St. Jude Medical, Partnership, Growth, Abbott Laboratories, Market for corporate control, Video game, Fossil fuel, Management, Finance

The Company is announcing preliminary unaudited financial results for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • The Company is announcing preliminary unaudited financial results for the fourth quarter and year ended December 31, 2022.
  • “We are pleased with the strong performance across our entire business in 2022,” said Paul Badawi, Founder and Chief Executive Officer of Sight Sciences.
  • The Company expects to announce complete fourth quarter and full year 2022 financial results in March 2023.
  • The select preliminary, unaudited results described in this press release are estimates only and are subject to revision until the Company reports its full financial and business results for the quarter and year ended December 31, 2022.

RVL Pharmaceuticals plc Announces Preliminary Fourth Quarter Sequential Growth of 21% and Full Year 2022 UPNEEQ® Net Product Sales

Retrieved on: 
Monday, January 9, 2023
Cardiovascular disease, Security (finance), Xanthine oxidase inhibitor, Hypertension, Orthostatic hypotension, Aneurysm, Eye injury, Glycosidic bond, Focal neurologic signs, Headache, Blood pressure, FDA, Risk, Food and Drug Administration, Ptosis, Hypotension, Glaucoma, Telehealth, Orbit, Blepharoplasty, Marketing, Patient, Food, Growth, Annual report, Metabolism, Horner's syndrome, Duane syndrome, Ophthalmoparesis, Stroke, RVL, Beta blocker, Nature, Eye, Myasthenia gravis, Pharmaceutical industry, Phosphorus

BRIDGEWATER, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced preliminary fourth quarter and full year 2022 net product sales of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, the first and only U.S. Food and Drug Administration (“FDA”)-approved ophthalmic solution for blepharoptosis, or droopy eyelids, of approximately $12.1 million and $36.5 million, respectively. The preliminary fourth quarter 2022 net product sales of UPNEEQ represent a sequential increase of 21% from the third quarter 2022. The Company also announced that from February through year-end 2022 it had received orders from approximately 4,300 cumulative unique medical aesthetics practices.

Key Points: 
  • The preliminary fourth quarter 2022 net product sales of UPNEEQ represent a sequential increase of 21% from the third quarter 2022.
  • “We are proud of our progress in the fourth quarter, notably the continued upward trajectory of net product sales for UPNEEQ.
  • On a full-year basis, we expect our UPNEEQ revenues to exceed $36 million, representing nearly 400% growth over 2021.
  • The financial and operating data for the fourth quarter of 2022 and for the full year 2022 is preliminary and may change.

AXIM® Biotechnologies CEO Issues Letter to Shareholders; Reminds of Conference Call

Retrieved on: 
Wednesday, January 11, 2023
Protein, DED, Research, Immunoglobulin E, Biomarker, CLIA, Eastern Time Zone, SAN, Trial of the century, Patient, Letter, Ophthalmology, Investment, FDA, Eastern Standard, Duane syndrome, Marketing, Biotechnology, Pharmaceutical industry, Medical device, Lactoferrin

SAN DIEGO, Jan. 11, 2023 /PRNewswire/ -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) ("AXIM Biotech," "AXIM" or "the Company"), an international healthcare diagnostic solutions development company, announced today that it has issued the following letter to its shareholders providing commentary on recent milestones achieved on its commercialized diagnostic solution platform and upcoming plans and goals for the new year and beyond.

Key Points: 
  • There is no doubt that AXIM has momentum in its favor and our opportunity has never been greater.
  • Leveraging our world-class science team, we focused our efforts on the area of ophthalmological conditions, specifically dry eye disease (DED).
  • As we announced in September, we signed an exclusive agreement with Verséa Ophthalmics to commercialize our two tests.
  • I am happy to report that they have been outstanding in generating interest and orders for our innovative solutions.

OKYO Pharma Limited - Interim Results for the Six Months Ending 30 September 2022

Retrieved on: 
Friday, December 30, 2022
Gabapentin, Peripheral neuropathy, MD, DED, Neuropathic pain, EU, File, NOW, AS, MA, Patient, Duane syndrome, Tufts University School of Medicine, FDA, IND, LSE, Tufts University School of Dental Medicine, OF, THIS, Pharmaceutical industry, Ophthalmology

LONDON and NEW YORK, Dec. 30, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announces its interim results for the six months ended 30 September 2022.

Key Points: 
  • LONDON and NEW YORK, Dec. 30, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announces its interim results for the six months ended 30 September 2022.
  • After considerable effort over the past 18 months, the Group announced on 21 November 2022 the filing of an IND on OK-101 with FDA to treat DED patients.
  • The Phase 2 trial is expected to be completed in 6-9 months from enrollment of the first patient.
  • UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.